Key result
Sirolimus-coated balloon matches paclitaxel-coated balloon for side branch diameter stenosis at 9 months.
Why the study?
The optimal strategy to treat coronary bifurcation lesions with main vessel stenting and side branch drug-coated balloons remains uncertain with limited evidence comparing sirolimus- and paclitaxel-coated balloons.
Does a sirolimus-coated balloon improve or maintain side branch diameter stenosis compared to a paclitaxel-coated balloon in patients with non-left main coronary bifurcation lesions?
RCT (n=230)
1:1
Yes
Does a sirolimus-coated balloon improve or maintain side branch diameter stenosis compared to a paclitaxel-coated balloon in patients with non-left main coronary bifurcation lesions?
In the treatment of de novo non-left main coronary bifurcation lesions, side branch dilation with a sirolimus-coated balloon is angiographically non-inferior to a paclitaxel-coated balloon at 9 months.
Answers are grounded in this paper and cite their sources.
Supports sirolimus DCB as alternative for side branch dilation in non-left main CBL; extends RCT evidence beyond paclitaxel devices.
BACKGROUND: The optimal strategy to treat coronary bifurcation lesions (CBL) has been a long-debated topic. The combination of a stent in the main vessel (MV) and a drug-coated balloon (DCB) in the side branch (SB) seems promising, but the evidence is limited. AIMS: This study aims to investigate a novel sirolimus-coated balloon in the treatment of non-left main CBL compared with a paclitaxel-coated balloon. METHODS: The SPACIOUS trial is a prospective, non-inferiority, multicentre trial. A total of 230 patients were randomised to the sirolimus DCB or the paclitaxel DCB group in a 1:1 ratio. Angiographic and clinical follow-ups were planned at 9 months and 1 year, respectively. The primary endpoint was diameter stenosis (DS) in the SB at 9 months. RESULTS: At 9 months, DS in the sirolimus group was 30.5±16.1% compared with 33.5±16.2% in the paclitaxel group (difference -2.94%; 95% confidence interval: -7.62% to 1.74%; p for non-inferiority<0.01). The incidence of binary restenosis was significantly lower in the sirolimus group compared to the paclitaxel group (4.4% vs 12.8%; p=0.043). Secondary angiographic endpoints, including late lumen loss and net lumen gain, and 1-year clinical outcomes were not significantly different between groups. CONCLUSIONS: In de novo non-left main CBL treatment, MV stenting accompanied by SB dilation with the sirolimus DCB was non-inferior to the paclitaxel DCB.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) conducted an RCT in Non-left main coronary bifurcation lesions (n=230). Sirolimus-coated balloon vs. Paclitaxel-coated balloon was evaluated on Diameter stenosis (DS) in the side branch at 9 months (MD -2.94%, 95% CI -7.62 to 1.74, p=<0.01 for non-inferiority). Side branch dilation with a sirolimus-coated balloon was non-inferior to a paclitaxel-coated balloon for diameter stenosis at 9 months.
Synapse has enriched 10 related papers. Consider them for comparative context: